real-time news and commentary for investors
Monday, Sep 23
Teva wins lawsuit against Mylan over IP for Parkinsons drug
- A U.S. District Court has upheld the validity of a Teva (TEVA +0.1%) patent that covers methods of treating Parkinson's disease and is related to the company's Azilect treatment.
- The ruling came after Teva sued Mylan (MYL -1.5%) for infringing the IP, and the Israeli company expects the court to prevent Mylan from launching its generic version of Azilect until Teva's patent expires in 2017.
- Teva has also filed a lawsuit suit against Sandoz, which has agreed to abide by the verdict in the case against Mylan. (PR)